Physician profile
Bryan Edward Saia
NPI 1841440377
$3,342.51
in general payments reported to CMS, 2019-2025
26 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $127 · 2021: $319 · 2022: $130 · 2023: $448 · 2024: $728 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $492.71 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $412.22 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $315.00 | 2022-2025 | Optimizer, Optimizer |
| Pfizer INC. | $300.88 | 2019-2025 | |
| Boston Scientific Corporation | $300.08 | 2019-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.15 | 2019-2025 | Jardiance |
| Abbott Laboratories | $248.19 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Perclose Prostyle |
| Janssen Pharmaceuticals, INC | $129.57 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $126.26 | 2020-2021 | |
| Amgen INC. | $120.28 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $97.67 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $69.83 | 2020-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $65.52 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $55.03 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $51.64 | 2024-2025 | Amvuttra, Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $44.82 | 2025 | |
| Merck Sharp & Dohme LLC | $42.58 | 2021-2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $31.32 | 2024 | Arcalyst |
| Novo Nordisk INC | $27.99 | 2019-2021 | |
| Inspire Medical Systems, INC. | $19.89 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $19.39 | 2022 | |
| Genzyme Corporation | $18.51 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2025 | |
| Kestra Medical Technology Services, INC. | $16.11 | 2024 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $15.77 | 2021 | |
| Heartflow, INC. | $14.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Saia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.